What a PSA Number Actually Means (and Why Men Avoid Asking)
There is one line on a men's blood panel that gets skipped more than any other. Men who track their sleep scores, their training volume, and their cholesterol trend will scroll right past PSA. Many have never asked for it.
The hesitation makes sense on the surface. PSA is associated with prostate cancer, and a test linked to cancer feels like a test best left alone until something seems off. If nothing is wrong, why go looking?
That reasoning runs backward. PSA is not a cancer test. It is a trend line, and a trend line only has value if you start it before you need it. This article explains what the number measures, what moves it, why a baseline in your 40s carries information you cannot get any other way, and why PSA and testosterone belong in the same conversation.
THE MARKER MEN SKIP
Most men's relationship with PSA is shaped by what they have heard secondhand: a friend's father who had a biopsy, a headline about overdiagnosis, a vague sense that the test causes more trouble than it prevents. None of that is a reason to stay uninformed about your own baseline. It is a reason to understand the number properly, so that a reading becomes data instead of a source of dread.
WHAT PSA IS
Prostate-specific antigen is a protein produced by cells in the prostate gland. Its normal function is mechanical: it helps keep semen liquid. Most of it stays where it belongs, but a small amount enters the bloodstream. A PSA blood test measures that amount in nanograms per milliliter (ng/mL).
The key word is "prostate-specific," not "cancer-specific." Every healthy prostate produces PSA. The number reflects prostate activity in general, which is why it is useful and why it requires interpretation.
WHAT MOVES THE NUMBER
Several ordinary things can raise PSA:
An enlarged prostate. Benign prostatic enlargement is common as men age, and more prostate tissue generally means more PSA.
Inflammation or infection. Prostatitis can push PSA up, sometimes sharply, and it often settles once the inflammation resolves.
Recent activity. Ejaculation and prolonged pressure on the prostate, such as long rides on a bike saddle, can raise PSA briefly.
Age. PSA tends to drift upward over decades, which is why the same reading means something different at 45 than at 65.
Testosterone. Raising testosterone can raise PSA modestly, which is covered in detail below.
Prostate cancer. Cancer cells can increase PSA, which is why the marker is used in early detection.
Some things lower PSA as well. Certain medications used for prostate enlargement and hair loss reduce PSA readings, which matters when your physician interprets the number.
WHY ONE READING IS NOT THE STORY
For years, 4.0 ng/mL was treated as a dividing line between "fine" and "concerning." That line was always an approximation. Many men with a reading above 4.0 do not have cancer, and some cancers are found in men below it.
Modern practice puts more weight on context: your age, your risk factors, your prostate size, and above all, how your number compares to your own earlier readings. Because PSA varies naturally from test to test, an unexpected result is typically confirmed with a repeat test before any decision is made. Even the rate of change has limits; the American Urological Association guideline advises against using PSA velocity alone as the reason for a biopsy.
The practical takeaway is simple. A single reading answers very few questions. A series of readings over years answers many.
THE CASE FOR A BASELINE IN YOUR 40s
Prostate cancer is the most common cancer in American men after skin cancer. The American Cancer Society estimates about 333,830 new cases in the US in 2026, and about 1 in 8 men will be diagnosed during his lifetime. Most men diagnosed do not die from it, and early detection is a large part of that outcome.
The strongest argument for a midlife baseline comes from long-term population data. The Malmo Preventive Project in Sweden stored blood samples from more than 21,000 men, most of whom were never screened, and followed them for decades. A 2013 analysis published in the BMJ found that men whose PSA was in the top 10 percent at ages 45 to 49 (a reading of 1.6 ng/mL or higher) accounted for 44 percent of later prostate cancer deaths. Men with a reading below the median at that age had a 15-year risk of metastasis under one tenth of one percent.
A later analysis of a contemporary North American cohort reached the same conclusion. For men aged 50 to 54, the estimated 20-year rate of lethal prostate cancer was 0.33 percent for those below the median PSA and 2.5 percent for those at or above the 90th percentile.
These findings cut in both directions, and that is the point. For most men, a low baseline is reassurance with real numbers behind it, and it supports testing less often. For a small group, it is an early signal that justifies closer attention, years before anything would otherwise surface. In both cases, the baseline replaces guessing with information.
WHAT THE GUIDELINES SAY (AND WHERE THEY DISAGREE)
The American Urological Association and Society of Urologic Oncology guideline, published in 2023 and amended in 2026, states that clinicians may offer a baseline PSA test between ages 45 and 50. For men at increased risk, which includes Black men, men with certain inherited gene mutations, and men with a strong family history of prostate cancer, the guideline says screening should be offered starting at 40 to 45. From 50 to 69, it recommends offering screening every 2 to 4 years, with the interval personalized to the individual.
The US Preventive Services Task Force takes a more cautious position. Its current recommendation treats screening for men aged 55 to 69 as an individual decision made with a clinician, citing the risk of false positives and of detecting slow-growing cancers that may never cause harm. Experts continue to debate where the balance sits.
What both positions share is a commitment to informed decision-making. A baseline PSA does not lock you into biopsies or interventions. It gives you and your physician a reference point so that future decisions are made with your own data rather than population averages.
WHY PSA AND TESTOSTERONE BELONG TOGETHER
For any man considering testosterone, PSA stops being optional.
Testosterone supports prostate tissue, and for decades clinicians worried that raising it would increase prostate cancer risk. The best evidence now available is reassuring for men who are properly evaluated first. The TRAVERSE trial randomized more than 5,000 men aged 45 to 80 with low testosterone to testosterone gel or placebo. In its prostate safety analysis, published in JAMA Network Open in 2023, high-grade prostate cancer occurred in 5 of 2,596 men on testosterone and 3 of 2,602 on placebo over more than 14,000 person-years of follow-up, a difference that was not statistically significant. PSA rose modestly more in the testosterone group.
Two details in that trial explain exactly why monitoring matters. First, men with a starting PSA above 3.0 ng/mL were excluded. The safety finding describes men who were screened before they began. Second, PSA moved, and the trial had predefined rules for what to do when it did.
The Endocrine Society's clinical practice guideline puts those rules into everyday practice. It calls for assessing prostate cancer risk before starting testosterone and again 3 to 12 months after. It recommends urology consultation if, during the first 12 months, there is a confirmed PSA increase of more than 1.4 ng/mL above baseline, a confirmed PSA above 4.0 ng/mL, or an abnormal prostate exam. The same guideline advises against starting testosterone in men with a PSA above 4.0 ng/mL, or above 3.0 ng/mL with high risk, until a urologist has evaluated them.
Every one of those checkpoints depends on a baseline. A prescription started without one leaves no way to tell whether a later number is normal drift or a meaningful change.
We covered the full monitoring picture, including estradiol, hematocrit, and free testosterone, in "Why TRT Isn't a Set-It-and-Forget-It Treatment." PSA is one of the anchors of that schedule.
GETTING AN ACCURATE READING
Because PSA responds to short-term activity, a few simple steps help make a reading meaningful. Many labs advise avoiding ejaculation and long or intense cycling for about 48 hours before the blood draw. Let your physician know about any recent urinary infection, prostate procedure, or medication that affects the prostate. If a result comes back higher than expected, a repeat test is the usual next step before drawing conclusions.
REFRAMING THE AVOIDANCE
Men who skip PSA usually believe they are avoiding risk. In practice, they are avoiding information. The prostate does what it does regardless of whether anyone measures it. Declining the test does not lower any risk. It only shortens the time available to respond if something changes.
The men who handle this well approach PSA the way they approach any other metric they care about. They want the baseline. They want the trend. They want to understand what moved and why. That posture is not anxious. It is the opposite of anxious, because nothing about the number arrives as a surprise.
WHERE PSA SITS ON THE SPRINGHOUSE MEN'S PANEL
At Springhouse, PSA is part of every Men's Panel, because hormones and prostate health are one conversation, not two. The complete panel includes: Testosterone Free and Total with SHBG, Estradiol LCMS, FSH and LH, Prolactin, PSA Total, CBC, CMP, Lipid Panel, TSH, and Hemoglobin A1C.
Reading PSA alongside testosterone, SHBG, and estradiol is what allows Dr. Lee-Agawa to interpret it in context, whether or not testosterone is ever part of the plan.
If you have never seen your PSA number, start with a $100 consultation. The deposit is applied toward services, including the Springhouse Men's Panel.
Springhouse Men's Wellness is a physician-founded practice led by Dr. Melissa Lee-Agawa, delivered in partnership with Grace & Glow MD. These articles are written by Taka Agawa, founder, with Dr. Lee-Agawa's clinical guidance throughout. Spring House, Pennsylvania. www.springhousemen.com
